Hypoglycemic and Hypolipidemic Swords: Synthesis and In-vivo Biological Assessment of 5-benzylidene-2,4-thiazolidinediones

Document Type : Research article

Authors

Department of Pharmaceutical Chemistry, Bharati Vidyapeeth’s College of Pharmacy, Navi Mumbai, India.

10.22037/ijpr.2021.114969.15131

Abstract

Thiazolidinedione (TZD), being a privileged scaffold, has been known as a significant structural moiety of antidiabetic drugs. TZD has been known to improve glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin sensitivity in the body. A novel series of 5-benzylidene 2,4-thiazolidinedione derivatives were designed, synthesized (V1-V28), and structurally confirmed by different spectroscopic techniques such as FTIR, 1H NMR, 13C NMR, and Mass spectrometry. Upon the safety assessment of the synthesized molecules in non-transformed hepatocytes by MTT reduction assay, these were found non-toxic. These derivatives were then further evaluated for their antihyperglycemic and antihyperlipidemic properties in a high-fat diet and low dose of streptozotocin-induced diabetic rats. Altogether, seven biochemical parameters were analyzed, namely blood glucose, triglycerides, cholesterol, creatinine, blood urea nitrogen, HDL-cholesterol, and glycosylated hemoglobin in serum by standard methods. Four synthetic molecules (V2, V4, V5, and V20) possessed significant hypoglycaemic and hypolipidemic activity as compared to the positive control pioglitazone. Moreover, the histopathological studies of the heart and liver revealed no significant toxicity. Two representative compounds V2 and V4, were evaluated for their PPARγ activation potential, demonstrating that they were partial PPARγ agonists, thus confirming our designing hypothesis. Based on the results obtained, we assume that these compounds have the potential to be developed as future antidiabetic agents.

Graphical Abstract

Hypoglycemic and Hypolipidemic Swords: Synthesis and In-vivo Biological Assessment of 5-benzylidene-2,4-thiazolidinediones

Keywords


References
(1) Diagnosis and Classification of Diabetes Mellitus.
Figure 5. PPARγ transactivation of test compounds against pioglitazone. Figure 5. PPARγ transactivation of test compounds against pioglitazone.
200
TZDs as Hypoglycemic and Hypolipidemic Swords
Diabetes Care (2013) 36: 67–74.
(2) Shaw JE, Sicree RA and Zimmet PZ. Global
estimates of the prevalence of diabetes for 2010
and 2030. Diabetes Res. Clin. Pract. (2010) 87:
4–14.
(3) Chawla A, Chawla R and Jaggi S. Microvasular and
macrovascular complications in diabetes mellitus:
Distinct or continuum? Indian J. Endocrinol.
Metab. (2016) 20: 546–551.
(4) Padhi S, Nayak AK and Behera A. Type II
diabetes mellitus: a review on recent drug based
therapeutics. Biomed. Pharmacother. (2020) 131:
110708.
(5) Feingold KR. Oral and Injectable (Non-Insulin)
Pharmacological Agents for Type 2 Diabetes. In:
Feingold KR, Anawalt B, Boyce A, Chrousos G,
de Herder WW, Dungan K, Dhatariya K, Hershman
JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp
P, Korbonits M, Kovacs CS, Kuohung W, Laferrère
B, Levy M, McGee EA, McLachlan R, Morley JE,
New M, Purnell J, Sahay R, Singer F, Sperling MA,
Stratakis CA, Trence DL and Wilson DP (eds.)
Endotext MDText.com, Inc., South Dartmouth
(MA) (2000) [cited 2021 Jan 13]. Available
from: URL: http://www.ncbi.nlm.nih.gov/books/
NBK279141/.
(6) Zhao ZH, Fan YC, Zhao Q, Dou CY, Ji XF,
Zhao J, Gao S, Li XY and Wang K. Promoter
methylation status and expression of PPAR-γ gene
are associated with prognosis of acute-on-chronic
hepatitis B liver failure. Clin. Epigenetics (2015)
7: 115.
(7) Fujita T, Sugiyama Y, Taketomi S, Sohda T,
Kawamatsu Y, Iwatsuka H and Suzouki Z. Reduction
of insulin resistance in obese and/or diabetic
animals by 5-[4-(1-methylcyclohexylmethoxy)
benzyl]-thiazolidine-2,4-dione (ADD-3878,
U-63,287, ciglitazone), a new antidiabetic agent.
Diabetes (1983) 32: 804–10.
(8) Rubenstrunk A, Hanf R, Hum D, Fruchart J and
Staels B. Safety issues and prospects for future
generations of PPAR modulators. Biochim.
Biophys. Acta Mol. Cell. Biol. Lipids (2007) 1771:
1065–81.
(9) Nissen SE and Wolski K. Effect of Rosiglitazone
on the Risk of Myocardial Infarction and Death
from Cardiovascular Causes. N. Engl. J. Med.
(2007) 356: 2457–71.
(10) Jones D. Potential remains for PPAR-targeted
drugs. Nat. Rev. Drug Discov. (2010) 9: 668–9.
(11) Grey A. Skeletal consequences of thiazolidinedione
therapy. Osteoporos Int. (2008) 19: 129–37.
(12) Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang
BB, Richards K, Elbretch A, Johnson BA, Zhou
G, Doebber TW, Biswas C, Parikh M, Sharma N,
Tanen MR, Thompson GM, Ventre J, Adams AD,
Mosley R, Surwit RS and Moller DE. Distinct
properties and advantages of a novel peroxisome
proliferator-activated protein γ selective modulator.
Mol. Endocrinol. (2003) 17: 662–76.
(13) Choi JH, Banks AS, Estall JL, Kajimura S,
Boström P and Laznik D . Anti-diabetic drugs
inhibit obesity-linked phosphorylation of PPARγ
by Cdk5. Nature (2010) 466: 451–6.
(14) Amato AA, Rajagopalan S, Lin JZ, Carvalho BM,
Figueira ACM, Lu J, Ayers SD, Mottin M, Silveira
RL, Souze PCT, Mourao RHV, Saad MJA, Togashi
M, Simeoni LA, Abdalla DS, Skaf MS, Polivparpov
I, Lima MCA, Galdino SL, Bernnan RG, Baxter
JD, Pitta IR, Webb P, Pillips K and Neves FAR.
GQ-16, a Novel Peroxisome Proliferator-activated
Receptor γ (PPARγ) Ligand, Promotes Insulin
Sensitization without Weight Gain. J. Biol. Chem.
(2012) 287: 28169–79.
(15) Choi JH, Banks AS, Kamenecka TM, Busby SA,
Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He
Y, Burning JB, Marciano DP, Cameron MD, Laznik
D, Jurkzak MJ, Schurer SC, Vidovic D, Shulman
GI, Spiegelman B and Griffin PR. Antidiabetic
actions of a non-agonist PPARγ ligand blocking
Cdk5-mediated phosphorylation. Nature (2011)
477: 477–81.
(16) Lee DH, Huang H, Choi K, Mantzoros C and
Kim YB. Selective PPARγ modulator INT131
normalizes insulin signaling defects and improves
bone mass in diet-induced obese mice. Am. J.
Physiol. Endocrinol. Metab. (2012) 302: 552–60.
(17) Li Zhou, Zhong Y, Xue MZ, Kuang D, Cao XW,
Zhao ZJ, Li HL, Xu YF and Wang R. Design,
synthesis and evaluation of PPAR gamma binding
activity of 2-thioxo-4-thiazolidinone derivatives.
Chin. Chem. Lett. (2014) 26: 63–8.
(18) Lu J, Lei L, Huan Y, Li Y, Zhang L, Shen Z, Hu
W and Feng Z. Design, synthesis, and activity
evaluation of GK/PPARγ dual-target-directed
ligands as hypoglycemic agents. ChemMedChem
(2014) 9: 922–7.
(19) Yasmin S, Capone F, Laghezza A, Piaz FD,
Loiodice F, Vijayan V, Devadasan V, Mondal S,
Atli O, Baysal M, Pattnaik AK, Jayaprakash V and
Levecchia A. Novel Benzylidene Thiazolidinedione
Derivatives as Partial PPARγ Agonists and their
Antidiabetic Effects on Type 2 Diabetes. Sci. Rep.
(2017) 7: 14453.
(20) Colca JR, VanderLugt JT, Adams WJ, Shashlo A,
McDonald WG, Liang J, Zhou R and Orloff DG.
Clinical Proof-of-Concept Study With MSDC0160, a Prototype mTOT-Modulating Insulin 
201
Patil V et al. / IJPR (2021), 20 (4): 188-201
Sensitizer. Clin. Pharmacol. Ther. (2013) 93: 352–
9.
(21) Mehendale-Munj S, Ghosh R and Ramaa CS.
Synthesis and evaluation of the hypoglycemic and
hypolipidemic activity of novel 5-benzylidene2,4-thiazolidinedione analogs in a type-2 diabetes
model. Med. Chem. Res. (2011) 20: 642–7.
(22) Joshi H, Patil V, Tilekar K, Upadhyay N, Gota V
and Ramaa CS. Benzylidene thiazolidinediones:
Synthesis, in-vitro investigations of antiproliferative
mechanisms and in vivo efficacy determination
in combination with Imatinib. Bioorganic Med.
Chem. Lett. (2020) 30: 127561.
(23) Patil V, Tilekar K, Mehendale-Munj S, Mohan
R and Ramaa CS. Synthesis and primary
cytotoxicity evaluation of new 5-benzylidene-2,
4-thiazolidinedione derivatives. Eur. J. Med.
Chem. (2010) 45: 4539–44.
(24) Joshi H, Marulkar K, Gota V and Ramaa CS.
Hydroxy Cinnamic Acid Derivatives as Partial
PPARγ Agonists: In-silico Studies, Synthesis
and Biological Characterization Against Chronic
Myeloid Leukemia Cell Line (K562). Anticancer
Agents Med. Chem. (2017) 17: 524–41.
(25) Srinivasan K, Viswanad B, Asrat L, Kaul CL and
Ramarao P. Combination of high-fat diet-fed and
low-dose streptozotocin-treated rat: a model for
type 2 diabetes and pharmacological screening.
Pharmacol. Res. (2005) 52: 313–20.
(26) Patil V, Tilekar K, Mehendale-Munj S, Mohan
R and Ramaa CS. Synthesis and primary
cytotoxicity evaluation of new 5-benzylidene-2,
4-thiazolidinedione derivatives. Eur. J. Med.
Chem. (2010) 45: 4539–44.
(27) Tilekar K, Upadhyay N, Jänsch N, Schweipert
M, Mrowka P, Meyer-Almes FJ and Ramaa
CS. Discovery of 5-naphthylidene-2,4-
thiazolidinedione derivatives as selective HDAC8
inhibitors and evaluation of their cytotoxic effects
in leukemic cell lines. Bioorg. Chem. (2020) 95:
103522.
(28) Vora D, Upadhyay N, Tilekar K, Jain V and Ramma
CS. Development of 1,2,4-triazole-5-thione
derivatives as potential inhibitors of enoyl acyl
carrier protein reductase (InhA) in tuberculosis.
Iran. J. Pharm. Sci. (2019) 18: 1742-58.
(29) Kabir A, Tilekar K, Upadhyay N and Ramaa
CS. Novel Anthraquinone Derivatives as Dual
Inhibitors of Topoisomerase 2 and Casein Kinase
2: In-silico Studies, Synthesis and Biological
Evaluation on Leukemic Cell Lines. Anticancer
Agents Med. Chem. (2018) 18: 1551–62